Market News Archives

February 25, 2026 – AI Trade Reignited: Nvidia’s Guidance Tops Forecasts, Nasdaq Leads Market Gains -( $AMT $DV $FIGS $GOVX $NOK $NVDA $QQQ $PLTR $SER $WDC Rise!)

by John F. Heerdink, Jr. February 25, 2026 1420Views 0Likes

US stocks extended this week’s rebound on Wednesday, February 25, 2026, with a tech-led advance ahead of and then through Nvidia’s blockbuster earnings release after the bell. Index performance The S&P 500 rose about 0.8% to roughly 6,946, marking a second…

February 24, 2026 – Stocks Rebound as Software Leads AI Relief Rally Ahead of Nvidia Earnings -( $AMD $CRM $DV $FIGS $IBRX $NVDA $OPEN $SER $SOAR $TSLA Rise!)

by John F. Heerdink, Jr. February 24, 2026 1132Views 0Likes

US stocks rebounded on Tuesday, February 24, 2026, with major indexes clawing back part of Monday’s AI-driven selloff as software and AI beneficiaries led a broad relief rally ahead of closely watched Nvidia earnings scheduled for tomorrow, Wednesday. Index performance The Dow Jones…

Nokia, AWS, and the Agentic AI Bet: When Telcos Meet Cloud Royalty -( $AMZN $NOK )

by John F. Heerdink, Jr. February 24, 2026 482Views 0Likes

In Barcelona’s annual parade of buzzwords, Nokia (NOK) and Amazon Web Services (AMZN) (AWS) have managed to turn “network slicing” and “agentic AI” into headliners rather than footnotes. The duo is unveiling what they describe as an industry‑first: an intent‑based, agentic AI‑powered…

Opendoor’s Q4 “Open House”: When Version 2.0 Actually Shows Up -( $OPEN $SPY )

by John F. Heerdink, Jr. February 24, 2026 485Views 0Likes

In a market that has spent three years asking whether iBuying is a feature or a business, Opendoor’s (OPEN) latest “Open House” suggests Opendoor 2.0 may finally be moving in. The company’s Q4 2025 results delivered faster growth in home acquisitions, improving…

Meta Hands AMD a 6-Gigawatt Vote of Confidence – And Wall Street Lights Up! – ( $AMD $META $NVDA )

by John F. Heerdink, Jr. February 24, 2026 465Views 0Likes

Meta Platforms (META) has inked a multi‑year pact to buy up to 6 gigawatts of AMD Instinct GPUs, a supersized order that instantly puts AMD at the center of one of the largest AI infrastructure build‑outs on the planet. The scale of…

Why Tandem Diabetes Care’s Convertible Notes and Modular Medical’s Pivot Pump Matter for Diabetes Investors -( $MDT $MODD $PODD $TNDM )

by John F. Heerdink, Jr. February 24, 2026 389Views 0Likes

Tandem Diabetes Care’s (TNDM) latest trip to the capital markets reads less like a distress signal and more like a company quietly extending its runway in a race it fully intends to finish. At the same time, a familiar name in diabetes…

Ivonescimab vs Keytruda: The High‑Stakes HARMONi‑3 Interim That Could Flip the Script for Summit Therapeutics -( $MRK $SMMT $IBB $XBI )

by John F. Heerdink, Jr. February 24, 2026 582Views 0Likes

Summit Therapeutics’ (SMMT) latest tweak to its clinical playbook has turned what was already one of biotech’s higher‑stakes stories into something closer to appointment viewing for Wall Street. A Phase 3 Trial Adds a Plot Twist Summit now plans an interim progression‑free…

Taleb, Citrini and the Birth of the AI Scare Trade – ( $NVDA $DIA $QQQ $SPY )

by John F. Heerdink, Jr. February 24, 2026 440Views 0Likes

Taleb, Citrini and the Birth of the AI Scare Trade Nassim Nicholas Taleb and Citrini Research have unintentionally become co-authors of Wall Street’s latest genre: the AI scare trade, where investors hedge against the possibility that the very technology powering the boom becomes…

February 23, 2026- Dow Sinks 800 Points as Tariffs and AI “Scare Trade” Rattle Wall Street -( $GOVX $INTG $MCD Rise!)

by John F. Heerdink, Jr. February 23, 2026 1012Views 0Likes

U.S. stocks sold off sharply on Monday as fresh tariff uncertainty from Washington and mounting concerns over AI-driven disruption sparked a broad risk-off move across Wall Street, driving a roughly 800‑point slide in the Dow and sending the S&P 500 and Nasdaq…

Gene Editing’s Next Act: How A Nobel Laureate Wants To Turn CRISPR From Hype To Habit

by John F. Heerdink, Jr. February 23, 2026 365Views 0Likes

In an era when artificial intelligence has stolen most of biotech’s buzz, gene editing is quietly trying to grow up from scientific marvel to dependable business line. At the center of that transition stands Nobel laureate Jennifer Doudna, who is now pairing…

Market News

Your Guide To Staying Informed In The Markets